PL3373959T3 - Cząstki arenawirusa jako szczepionki przeciwrakowe - Google Patents

Cząstki arenawirusa jako szczepionki przeciwrakowe

Info

Publication number: PL3373959T3
Authority: PL; Poland
Prior art keywords: cancer vaccines; arenavirus particles; arenavirus; particles; vaccines
Prior art date: 2015-11-12

Application number

PL16797775.0T

Other languages

English (en)

Inventor

Sarah Schmidt

Klaus Orlinger

Katherine Cohen

Original Assignee

Hookipa Biotech Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-04

Publication date

2022-10-24

2016-11-04 Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh

2022-10-24 Publication of PL3373959T3 publication Critical patent/PL3373959T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001108—Platelet-derived growth factor receptors [PDGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001138—Tumor necrosis factors [TNF] or CD70
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/001159—Matrix metalloproteinases [MMP]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/00116—Serine proteases, e.g. kallikrein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001172—Sialyl-Thomson-nouvelle antigen [sTn]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Developmental Biology & Embryology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)

PL16797775.0T 2015-11-12 2016-11-04 Cząstki arenawirusa jako szczepionki przeciwrakowe PL3373959T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562254651P	2015-11-12	2015-11-12
US201562254654P	2015-11-12	2015-11-12
PCT/EP2016/076668 WO2017080920A1 (en)	2015-11-12	2016-11-04	Arenavirus particles as cancer vaccines

Publications (1)

Publication Number	Publication Date
PL3373959T3 true PL3373959T3 (pl)	2022-10-24

Family

ID=57345877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16797775.0T PL3373959T3 (pl)	2015-11-12	2016-11-04	Cząstki arenawirusa jako szczepionki przeciwrakowe

Country Status (16)

Country	Link
US (2)	US11266727B2 (pl)
EP (2)	EP3373959B1 (pl)
JP (2)	JP7157662B2 (pl)
CN (1)	CN108697775B (pl)
AU (1)	AU2016352572B2 (pl)
CA (1)	CA3003548A1 (pl)
DK (1)	DK3373959T3 (pl)
ES (1)	ES2922981T3 (pl)
HR (1)	HRP20221167T1 (pl)
HU (1)	HUE059589T2 (pl)
LT (1)	LT3373959T (pl)
PL (1)	PL3373959T3 (pl)
PT (1)	PT3373959T (pl)
RS (1)	RS63546B1 (pl)
SI (1)	SI3373959T1 (pl)
WO (1)	WO2017080920A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5642556B2 (ja)	2007-12-27	2014-12-17	ユニヴァーシテトチューリッヒ	複製欠損アレナウイルスベクター
WO2015082570A1 (en)	2013-12-03	2015-06-11	Hookipa Biotech Ag	Cmv vaccines
RS60937B1 (sr)	2014-11-13	2020-11-30	Univ Geneve	Tri-segmentirani arenavirusi kao vektori za vakcinu
CA2987155A1 (en)	2015-06-10	2016-12-15	Hookipa Biotech Ag	Hpv vaccines
WO2018045029A1 (en) *	2016-09-02	2018-03-08	The United States Of America, As Represented By The Secretary Of The Army	Pan south american arenavirus live attenuated vaccine
KR20250107977A (ko)	2015-11-04	2025-07-14	후키파 바이오테크 게엠베하	B형 간염 바이러스에 대한 백신
PL3373959T3 (pl)	2015-11-12	2022-10-24	Hookipa Biotech Gmbh	Cząstki arenawirusa jako szczepionki przeciwrakowe
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP2020516601A (ja) *	2017-04-07	2020-06-11	ホオキパバイオテックジーエムビーエイチ	固形腫瘍を治療するためのアレナウイルス粒子
EP3717002A1 (en) *	2017-11-29	2020-10-07	Adaptive Phage Therapeutics, Inc.	Methods of vaccination using icosahedral phage
CA3143421A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
EP4055173A1 (en) *	2019-11-07	2022-09-14	Universität Basel Vizerektorat Forschung	Arenaviruses as vectors
AU2020397499A1 (en)	2019-12-07	2022-06-16	Erasmus University Medical Center Rotterdam	Treatment of diseases related to hepatitis B virus
WO2021239471A1 (en)	2020-05-29	2021-12-02	Hookipa Biotech Gmbh	Cancer treatment strategies using arenavirus vectors
EP4297763A1 (en) *	2021-02-26	2024-01-03	Abalos Therapeutics GmbH	New virus particles for therapeutic purposes
JP2024512566A (ja)	2021-03-23	2024-03-19	ホオキパバイオテックジーエムビーエイチ	前立腺癌の治療に使用されるアレナウイルス
US20250057931A1 (en) *	2022-02-08	2025-02-20	Hookipa Biotech Gmbh	Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
EP4701650A2 (en)	2023-04-26	2026-03-04	Isabella Pharma B.V.	Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
JPH1084967A (ja)	1996-09-19	1998-04-07	Fujirebio Inc	Ｂ型肝炎のｅ抗原
FR2803599B1 (fr)	2000-01-06	2004-11-19	Inst Nat Sante Rech Med	Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications
PT1537878E (pt)	2002-07-03	2010-11-18	Ono Pharmaceutical Co	Composições de imunopotenciação
CN103059138B (zh)	2005-05-09	2015-10-28	小野药品工业株式会社	程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2006125983A1 (en)	2005-05-23	2006-11-30	Oxxon Therapeutics Ltd	Compositions for inducing an immune response against hepatitis b
EP2010537B1 (en)	2006-03-23	2011-12-28	Novartis AG	Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en)	2006-03-23	2012-06-27	Novartis AG	Immunopotentiating compounds
JP5623747B2 (ja) *	2006-12-27	2014-11-12	エモリーユニバーシティ	感染症および腫瘍を処置するための組成物および方法
JP5642556B2 (ja)	2007-12-27	2014-12-17	ユニヴァーシテトチューリッヒ	複製欠損アレナウイルスベクター
EP2461826A2 (en)	2009-08-07	2012-06-13	Transgene SA	Composition for treating hbv infection
GB201001726D0 (en)	2010-02-03	2010-03-24	Univ St Andrews	Bunyavirus vaccine
WO2012162428A1 (en)	2011-05-23	2012-11-29	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prime-boost vaccination for viral infection
US9492526B2 (en)	2012-01-24	2016-11-15	Sanford Health	Polynucleotides for treating oncogenic viral polypeptide positive tumors
ES2751423T3 (es)	2013-03-15	2020-03-31	Univ Geneve	Vacunas antimicobacterianas
GB201305361D0 (en)	2013-03-25	2013-05-08	Univ Edinburgh	Enhanced expression
WO2015082570A1 (en)	2013-12-03	2015-06-11	Hookipa Biotech Ag	Cmv vaccines
WO2015103602A1 (en)	2014-01-06	2015-07-09	The Trustees Of The University Of Pennsylvania	Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US10342861B2 (en)	2014-05-27	2019-07-09	University Of Rochester	Arenavirus vaccine
US9943585B2 (en)	2014-07-30	2018-04-17	University Of Rochester	Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
WO2016048949A1 (en)	2014-09-22	2016-03-31	Regents Of The University Of Minnesota	Pichinde virus reverse genetics system and methods of use
GB201419572D0 (en)	2014-11-03	2014-12-17	Pirbright Inst The	Virus
RS60937B1 (sr)	2014-11-13	2020-11-30	Univ Geneve	Tri-segmentirani arenavirusi kao vektori za vakcinu
CA2974956A1 (en) *	2015-01-29	2016-08-04	The Trustees Of The University Of Pennsylvania	Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
DE102015207036A1 (de)	2015-04-17	2016-10-20	Karl Sebastian Lang	Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CA2987155A1 (en)	2015-06-10	2016-12-15	Hookipa Biotech Ag	Hpv vaccines
US10849969B2 (en)	2015-10-23	2020-12-01	Institut Pasteur	Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
KR20250107977A (ko)	2015-11-04	2025-07-14	후키파 바이오테크 게엠베하	B형 간염 바이러스에 대한 백신
PL3373959T3 (pl)	2015-11-12	2022-10-24	Hookipa Biotech Gmbh	Cząstki arenawirusa jako szczepionki przeciwrakowe
US10980877B2 (en)	2016-04-28	2021-04-20	The University Of Chicago	Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
CA3023599A1 (en)	2016-05-18	2017-11-23	Hookipa Biotech Gmbh	Tri-segmented pichinde viruses as vaccine vectors
CN110167586B (zh)	2016-11-04	2024-01-30	霍欧奇帕生物科技有限公司	作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒
JP2020516601A (ja)	2017-04-07	2020-06-11	ホオキパバイオテックジーエムビーエイチ	固形腫瘍を治療するためのアレナウイルス粒子
EP4055173A1 (en)	2019-11-07	2022-09-14	Universität Basel Vizerektorat Forschung	Arenaviruses as vectors

2016
- 2016-11-04 PL PL16797775.0T patent/PL3373959T3/pl unknown
- 2016-11-04 LT LTEPPCT/EP2016/076668T patent/LT3373959T/lt unknown
- 2016-11-04 ES ES16797775T patent/ES2922981T3/es active Active
- 2016-11-04 JP JP2018524447A patent/JP7157662B2/ja active Active
- 2016-11-04 RS RS20220825A patent/RS63546B1/sr unknown
- 2016-11-04 EP EP16797775.0A patent/EP3373959B1/en active Active
- 2016-11-04 HR HRP20221167TT patent/HRP20221167T1/hr unknown
- 2016-11-04 AU AU2016352572A patent/AU2016352572B2/en active Active
- 2016-11-04 CN CN201680078633.1A patent/CN108697775B/zh active Active
- 2016-11-04 HU HUE16797775A patent/HUE059589T2/hu unknown
- 2016-11-04 SI SI201631604T patent/SI3373959T1/sl unknown
- 2016-11-04 EP EP21182026.1A patent/EP3960197A1/en active Pending
- 2016-11-04 WO PCT/EP2016/076668 patent/WO2017080920A1/en not_active Ceased
- 2016-11-04 PT PT167977750T patent/PT3373959T/pt unknown
- 2016-11-04 CA CA3003548A patent/CA3003548A1/en active Pending
- 2016-11-04 DK DK16797775.0T patent/DK3373959T3/da active
- 2016-11-04 US US15/775,360 patent/US11266727B2/en active Active
2021
- 2021-11-02 JP JP2021179213A patent/JP2022033736A/ja active Pending
2022
- 2022-01-24 US US17/582,682 patent/US20220257734A1/en active Pending

Also Published As

Publication number	Publication date
DK3373959T3 (da)	2022-09-19
EP3960197A1 (en)	2022-03-02
WO2017080920A1 (en)	2017-05-18
JP2022033736A (ja)	2022-03-02
RS63546B1 (sr)	2022-09-30
HRP20221167T1 (hr)	2022-12-09
EP3373959B1 (en)	2022-06-29
LT3373959T (lt)	2022-07-25
SI3373959T1 (sl)	2022-11-30
AU2016352572B2 (en)	2023-10-19
US11266727B2 (en)	2022-03-08
EP3373959A1 (en)	2018-09-19
HUE059589T2 (hu)	2022-12-28
CA3003548A1 (en)	2017-05-18
AU2016352572A1 (en)	2018-05-17
CN108697775B (zh)	2023-05-09
PT3373959T (pt)	2022-08-09
CN108697775A (zh)	2018-10-23
US20180344830A1 (en)	2018-12-06
ES2922981T3 (es)	2022-09-22
US20220257734A1 (en)	2022-08-18
JP7157662B2 (ja)	2022-10-20
JP2018533604A (ja)	2018-11-15

Publication	Publication Date	Title
ZA202005298B (en)	2022-02-23	Combination tumor immunotherapy
PT3373959T (pt)	2022-08-09	Partículas de arenavírus como vacinas contra o cancro
IL251464A0 (en)	2017-05-29	Combination therapy for cancer
GB201518684D0 (en)	2015-12-02	Vaccine
GB201410971D0 (en)	2014-08-06	Vaccine
IL249898A0 (en)	2017-03-30	Combined cancer treatment
IL246761A0 (en)	2016-08-31	Combined cancer treatment
GB201522132D0 (en)	2016-01-27	Vaccine
IL277752A (en)	2020-11-30	Cancer vaccines
EP3122375A4 (en)	2018-04-18	Breast and ovarian cancer vaccines
PL3322718T3 (pl)	2024-04-22	Histonowe szczepionki przeciwnowotworowe
GB201608821D0 (en)	2016-07-06	Vaccines
GB201519734D0 (en)	2015-12-23	Cancer therapy
GB201508480D0 (en)	2015-07-01	Cancer
SI3188755T1 (sl)	2021-03-31	Cepivo
ZA201708393B (en)	2019-06-26	Large particles
HK40058005B (zh)	2026-02-13	乳腺癌和卵巢癌疫苗
GB201417214D0 (en)	2014-11-12	Vaccine
GB201406628D0 (en)	2014-05-28	Vaccine
HK1259853A1 (en)	2019-12-06	Cancer vaccines
GB201518917D0 (en)	2015-12-09	Vaccination
GB201503266D0 (en)	2015-04-15	Vaccination
GB201411884D0 (en)	2014-08-20	Cancer therapy
GB201521608D0 (en)	2016-01-20	Vaccine composition
GB201507344D0 (en)	2015-06-10	Novel particles